Results 101 to 110 of about 46,891 (297)
Epilepsia Open, EarlyView.Abstract Objective Ketogenic dietary therapies (KDTs) are the treatment of choice for Glut1 Deficiency Syndrome (Glut1DS), providing dietary ketones as an alternative fuel to the brain and effectively controlling seizures. Recent evidence indicates insufficient seizure control in Glut1DS patients despite adequate KDT and ketosis.
Joerg Klepper, Eva Runkel, Lucia Kiesel
wiley +1 more source
Epilepsia Open, EarlyView.Abstract Objectives Dravet syndrome (DS) is a drug‐resistant developmental and epileptic encephalopathy, often requiring three or more antiseizure medications (ASMs). Consequently, the therapeutic landscape is highly complex, combining DS‐specific agents (stiripentol, STP; cannabidiol, CBD; fenfluramine, FFA), non‐specific ASMs, and non‐pharmacologic ...
J. Helen Cross +4 more
wiley +1 more source
Pharmacokinetic Interaction of Kratom and Cannabidiol in Male Rats
PharmaceuticsKratom and cannabidiol products are used to self-treat a variety of conditions, including anxiety and pain, and to elevate mood. Research into the individual pharmacokinetic properties of commercially available kratom and cannabidiol products has been ...
Erin C. Berthold +8 more
doaj +1 more source
Cannabidiol for psychosis: A review of 4 studies [PDF]
, 2020 Sy Atezaz Saeed, Kathryn E Clary
openalex +1 more source
Transcriptome Analysis of Cisplatin, Cannabidiol, and Intermittent Serum Starvation Alone and in Various Combinations on Colorectal Cancer Cells [PDF]
, 2023 Viktoriia Cherkasova +3 more
openalex +1 more source
Epilepsia Open, EarlyView.Abstract Objective Cenobamate (CNB) is a highly effective antiseizure medication (ASM) for focal drug‐resistant epilepsy (DRE); nevertheless, even with CNB treatment and optimized therapy, a substantial proportion of patients continued to experience seizures.
Ilaria Ciullo +8 more
wiley +1 more source
PLoS ONE, 2019 Recent evidence has raised in discussion the possibility that cannabidiol can act as a negative allosteric modulator of the cannabinoid type 1 receptor. Here we have used computational methods to study the modulation exerted by cannabidiol on the effects
Hery Chung +2 more
doaj +1 more source
Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature. [PDF]
, 2019 Fragile X syndrome (FXS) is an X-linked dominant disorder caused by a mutation in the fragile X mental retardation 1 gene. Cannabidiol (CBD) is an exogenous phytocannabinoid with therapeutic potential for individuals with anxiety, poor sleep, and ...
Bonn-Miller, Marcel +2 more
core
Research progress on the role of inflammatory mediators in the pathogenesis of epilepsy
Ibrain, Volume 11, Issue 1, Page 44-58, Spring 2025.In the central nervous system, activated immune cells lead to the overproduction of inflammatory mediators through the corresponding signal pathway. Under the stimulation of inflammatory factors, neuroinflammation ultimately occurs. Overexpression of inflammatory mediators and activated immunocytes plays an important role in the emergence and ...
Yue Yu, Fei‐Ji Sun
wiley +1 more source
Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome [PDF]
, 2020 Évila Lopes Salles +9 more
openalex +1 more source